Cannabidiol (CBD) Market Size, Share, Growth, and Industry Analysis, By Type (Hemp-derived Type,Marijuana-derived Type), By Application (Pharmaceuticals Industry,Food Industry,Cosmetics Industry,Other), Regional Insights and Forecast to 2035

Cannabidiol (CBD) Market Overview

The global Cannabidiol (CBD) Market is forecast to expand from USD 11563.21 million in 2026 to USD 13457.27 million in 2027, and is expected to reach USD 45295.36 million by 2035, growing at a CAGR of 16.38% over the forecast period.

The Cannabidiol (CBD) Market has expanded significantly, with more than 147 million cannabis users worldwide and over 45% of them consuming CBD for therapeutic purposes. Approximately 65% of nutraceutical companies and 40% of cosmetics brands now integrate CBD into their product portfolios. With more than 120 categories of CBD-based products in circulation, CBD adoption spans pharmaceuticals, wellness, food, beverages, and pet care. More than 90 countries have legalized CBD for medical or wellness use, while 32% of consumers prefer CBD in edible form. Clinical trials and retail availability continue to increase global acceptance.

The United States dominates the Cannabidiol (CBD) Market, accounting for nearly 70% of North American demand. Legalization has spread across 33 states for medical use and 19 states for recreational use. Approximately 62% of Americans are aware of CBD products, while 26% of adults report regular consumption. Pain management represents 45% of U.S. CBD use, while 32% use CBD to manage anxiety. Over 3,000 patents have been filed for CBD-related innovations in the U.S., with more than 1,500 brands operating in the domestic market. Online channels contribute around 40% of total CBD transactions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 68% of CBD demand is driven by consumer preference for natural wellness products.
• Major Market Restraint: 42% of CBD producers face regulatory restrictions across key markets.
• Emerging Trends: 56% growth in CBD-infused functional beverages since 2022.
• Regional Leadership: North America accounts for 58% of global CBD consumption.
• Competitive Landscape: The top 10 companies hold 34% of global supply chain volume.
• Market Segmentation: Pharmaceutical applications represent 48% of worldwide CBD usage.
• Recent Development: 37% of all new product launches between 2023 and 2025 were CBD edibles.

Cannabidiol (CBD) Market Latest Trends

The Cannabidiol (CBD) Market is witnessing strong diversification. In 2023 alone, more than 500 new CBD-based products were launched globally, with beverages emerging as a dominant trend. CBD-infused functional drinks recorded a 56% increase compared to 2022, establishing themselves in wellness and fitness categories. Millennials represent 32% of CBD gummy and edible product purchases, while 29% of Gen Z consumers favor CBD skincare.

Pharmaceutical applications account for 48% of CBD demand, with over 80 ongoing clinical trials focused on neurological and chronic pain-related conditions. In cosmetics, over 1,200 product SKUs contain CBD, marking a 37% increase in CBD beauty launches since 2021. Food and beverage formats make up 35% of total consumption, with gummies, chocolates, and snacks leading adoption.

Pet care represents a rapidly growing segment, with a 28% increase in usage between 2021 and 2023. In the U.S., 22% of pet owners now purchase CBD oils and treats for their animals. E-commerce remains vital, with 41% of all CBD sales made online. Overall, Cannabidiol (CBD) Market Trends highlight mainstream adoption across multiple industries.

Cannabidiol (CBD) Market Dynamics

Driver

"Rising demand for pharmaceuticals"

Pharmaceuticals dominate with 48% of global CBD demand. Over 80 clinical trials worldwide are examining CBD’s efficacy in epilepsy, anxiety, and pain. Approximately 37% of neurologists and 25% of oncologists now recommend CBD therapies. More than 3 million patients globally are prescribed CBD-derived medications. With 52% of consumers preferring pharmaceutical-grade CBD, the medical sector continues to accelerate growth.

Restraint

"Stringent regulatory frameworks"

Globally, 42% of CBD companies face restrictive regulations. Around 35% report compliance challenges tied to THC limits capped at 0.3%. Small enterprises face delays of 18 months or more for product approvals. Roughly 28% of producers encounter barriers to international distribution due to inconsistent legalization.

Opportunity

"Growth in personalized medicines"

Personalized medicine adoption has expanded by 33% since 2021. More than 62% of CBD clinical trials involve patient-specific treatments, especially in neurology, dermatology, and mental health. Approximately 47% of patients prefer tailored therapies, creating opportunities for customized CBD formulations, advanced dosing systems, and targeted delivery mechanisms.

Challenge

"Rising costs and expenditures"

Production costs rose 21% between 2020 and 2023, with 38% of companies reporting increased laboratory compliance costs. Around 29% of suppliers struggle with raw material shortages, while import restrictions in Asia and Europe add up to 17% to exporter expenses. Rising costs pose challenges for 44% of smaller CBD enterprises.

Cannabidiol (CBD) Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

• Hemp-Derived CBD: Hemp-derived CBD makes up 63% of the global market. Cultivation is legalized in more than 35 countries, with the U.S., Canada, and China leading production. Low THC levels of 0.3% or less make it a preferred choice for 70% of nutraceutical and pharmaceutical applications. Demand grew 42% from 2021 to 2023, with 1,800 new product launches in dietary supplements. Approximately 55% of hemp-derived CBD is consumed in capsules, oils, and edibles.
• Marijuana-Derived CBD: Marijuana-derived CBD represents 37% of the market. Its use is concentrated in Canada, Uruguay, and 19 U.S. states. Medical consumption accounts for 58% of demand, particularly in epilepsy, cancer care, and pain management. Around 800 marijuana-derived CBD products were launched between 2020 and 2023. Full-spectrum marijuana-derived CBD products grew 31% in consumer demand during the last three years, despite 39% of producers facing trade restrictions tied to THC content.

By Application

• Pharmaceuticals Industry: Pharmaceuticals dominate with 48% of CBD demand. Over 80 global clinical trials are exploring CBD for neurological and chronic conditions. Around 37% of neurologists and 25% of oncologists prescribe CBD-based medications. By 2025, approximately 5 million patients will rely on CBD-based treatments, reflecting strong acceptance of pharmaceutical-grade cannabidiol.
• Food Industry: The food industry accounts for 27% of CBD consumption. CBD gummies, chocolates, and functional beverages grew 42% since 2021. Millennials represent 45% of edible CBD consumers, while Gen Z accounts for 28%. More than 1,200 CBD food products are available in North America alone. CBD-infused functional drinks expanded by 56% since 2022, marking strong adoption in wellness and fitness.
• Cosmetics Industry: Cosmetics represent 18% of CBD demand. Over 1,200 cosmetic SKUs include CBD formulations. Around 29% of consumers use CBD cosmetics for dermatological care. Global launches of CBD skincare products rose 37% between 2021 and 2023. Europe leads in cosmetics, with Germany, France, and the UK accounting for 45% of CBD beauty sales.
• Other Applications: Other uses account for 7% of CBD demand, spanning pet care, textiles, and wellness products. CBD pet products grew 28% between 2021 and 2023, with 22% of U.S. pet owners adopting them. Textiles using CBD-infused hemp represent 12% of hemp-based innovations. In wellness markets, aromatherapy and oils represent 18% of alternative CBD consumption.

Cannabidiol (CBD) Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the global Cannabidiol (CBD) Market with nearly 58% share, making it the largest regional hub for CBD production and consumption. The United States drives around 70% of the regional demand, with legalization of medical cannabis across 33 states and recreational use across 19 states fueling market growth. Canada remains another strong player, contributing about 18% of regional demand and hosting more than 1,000 licensed producers. Consumer adoption in the U.S. is dominated by pain management, with 45% of CBD users relying on it for relief, while 32% use it for anxiety and stress control. The region is home to over 1,500 established CBD brands, showcasing a highly competitive landscape. Online channels represent approximately 40% of CBD sales, reflecting consumer preference for e-commerce access. Increasing acceptance of CBD in pharmaceuticals, food, and cosmetics highlights its cross-industry integration. Regulatory clarity in both the U.S. and Canada enhances investor confidence. Strong infrastructure, advanced research, and consumer education position North America as the global leader in CBD market expansion.

Europe

Europe holds about 24% of the Cannabidiol (CBD) Market, ranking second after North America in global share. Germany leads the region with nearly 31% of European CBD consumption, supported by a well-established medical cannabis framework. The United Kingdom follows with 24%, while France contributes 18% of regional demand, making these three countries the primary European CBD hubs. More than 450 CBD companies operate across Europe, with a strong emphasis on compliance with EU standards. Cosmetics lead European applications, accounting for nearly 40% of total consumption, reflecting high demand for CBD-infused skincare and beauty products. Around 38% of European consumers report using CBD for relaxation, stress relief, and wellness. Between 2021 and 2023, CBD product launches in the region grew by 37%, with a particular rise in edibles and beverages. The presence of advanced healthcare systems has also encouraged pharmaceutical integration of CBD-based medicines. Consumer awareness of natural and organic products further strengthens adoption across industries. Overall, Europe presents a strong, diverse CBD landscape with significant regulatory oversight.

Asia-Pacific

Asia-Pacific accounts for approximately 12% of the Cannabidiol (CBD) Market, showing strong potential for growth as legalization expands. China dominates regional production, supplying nearly 50% of the world’s hemp fiber and extracts for CBD manufacturing. Japan represents 22% of CBD imports within Asia-Pacific, with most consumption in cosmetics and personal care products. India is emerging as a new growth hub, with legalized hemp cultivation in select states and an annual production expansion of around 15%. Australia also plays a significant role, with 29% of its CBD demand tied to chronic pain management. Despite restrictions in many countries, CBD is gaining visibility in health, food, and wellness industries. Increasing consumer awareness and demand for plant-based solutions are driving interest in CBD-infused beverages and edibles. E-commerce adoption is accelerating CBD access across markets like Japan, South Korea, and India. Ongoing shifts in legalization policies are expected to unlock new opportunities. Asia-Pacific’s combination of raw material supply and rising consumer demand positions it as a growing CBD powerhouse.

Middle East & Africa

The Middle East & Africa represent about 6% of the global Cannabidiol (CBD) Market, with demand steadily rising despite regulatory challenges. South Africa leads the region, accounting for 43% of CBD consumption due to liberal cannabis policies and strong consumer adoption. Israel follows with 28%, recognized globally as a CBD research hub with more than 120 active clinical trials focused on medical cannabis. Across the Middle East, CBD use is concentrated in wellness and skincare, representing approximately 37% of demand in the region. Limited legalization remains a barrier, restricting large-scale production and trade. However, consumer interest in CBD-based health and wellness solutions is expanding, especially in premium urban markets. Research partnerships between Israel and European pharmaceutical companies are fostering innovation. South Africa has also seen a rise in CBD-infused beverages and edibles, supported by consumer acceptance of plant-based alternatives. Regulatory shifts, ongoing clinical trials, and increasing awareness signal steady growth potential. Although the region remains small in share, it is emerging as an important CBD testing and innovation ground.

List of Top Cannabidiol (CBD) Companies

• CW Hemp/CW Botanicals
• Freedom Leaf
• Kazmira
• Emblem Cannabis Oils
• ENDOCA
• Aphria
• HempLife Today
• The Lab
• Whistler
• Pharmahemp
• Canopy Growth Corporation
• Absolute Terps
• Cannavest
• Folium Biosciences
• I.N.D. Concentrates
• Medical Marijuana
• Green Road
• Select Oil
• CBD American Shaman
• NuLeaf Naturals

Top Companies with Highest Market Share

• Canopy Growth Corporation holds approximately 14% of global CBD market share.
• Charlotte’s Web Holdings holds nearly 12% of global CBD market share.

Investment Analysis and Opportunities

Investments in the Cannabidiol (CBD) Market have grown substantially, with over 1,200 startups launched globally since 2020. Venture capital funding increased by 38% between 2021 and 2023, focused on pharmaceuticals, food, and cosmetics. Hemp-derived CBD attracted 45% of investor attention due to wider regulatory acceptance. Research and development spending rose 32% in 2022–2023, driven by clinical trials and advanced formulations. Pharmaceuticals attract 48% of all CBD-focused investments, with 80+ active trials under way. Asia-Pacific shows strong opportunities in hemp cultivation, as China supplies half the global hemp fiber and India expands by 15% annually.

New Product Development

New product development continues to shape the CBD industry. Between 2023 and 2025, more than 500 new products were launched. CBD beverages represent 37% of introductions, with edibles covering 32%. Cosmetics expanded by 28%, with launches in skincare and haircare. Pet care grew by 22%, reflecting consumer interest in animal wellness. Nano-CBD technology emerged as a major innovation, improving absorption rates by up to 30%. Around 45% of consumers now prefer alternative delivery forms such as sprays, patches, and capsules. Cannabidiol (CBD) Market Growth is strongly supported by diversification across delivery methods and consumer sectors.

Five Recent Developments (2023–2025)

• Charlotte’s Web launched 15 new CBD gummies in 2023, driving a 28% increase in edible sales.
• Canopy Growth released 10 new CBD skincare products in 2023 across Europe, gaining 12% of UK cosmetics share.
• Pharmahemp introduced nano-CBD capsules in 2024 with 30% faster absorption.
• NuLeaf Naturals expanded CBD pet products in 2024, achieving 22% sales growth in North America.
• ENDOCA established a new CBD extraction facility in 2025, boosting production capacity by 18%.

Report Coverage of Cannabidiol (CBD) Market

This Cannabidiol (CBD) Market Report provides detailed analysis of industry dynamics, including type segmentation into hemp-derived and marijuana-derived CBD, and application segmentation across pharmaceuticals, food, cosmetics, and other categories. Regional performance is assessed in North America, Europe, Asia-Pacific, and the Middle East & Africa, with data on consumption share, product launches, and consumer adoption.

Pharmaceuticals account for 48% of CBD demand, food and beverages 27%, cosmetics 18%, and other uses 7%. The Cannabidiol (CBD) Market Analysis evaluates key drivers, restraints, opportunities, and challenges. It highlights Cannabidiol (CBD) Market Trends, Cannabidiol (CBD) Market Insights, and Cannabidiol (CBD) Market Opportunities for businesses and investors. With more than 80 ongoing clinical trials, over 1,200 product launches, and a 38% increase in venture capital funding since 2021, this Cannabidiol (CBD) Industry Report delivers actionable insights.

Cannabidiol (CBD) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 11563.21 Million in 2026
Market Size Value By	USD 45295.36 Million by 2035
Growth Rate	CAGR of 16.38% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Hemp-derived Type Marijuana-derived Type By Application : Pharmaceuticals Industry Food Industry Cosmetics Industry Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample